Robusta Coffee (Coffea canephora): A Comprehensive Reference
1. Identity: Botanical Name, Source, and Common Forms
1.1 Botanical Classification and Nomenclature
Robusta coffee (Coffea canephora subvar. robusta, syn. Coffea robusta) is a species of coffee plant originating in central and western sub-Saharan Africa and a member of the family Rubiaceae. Though widely known commercially as Coffea robusta, the plant is scientifically identified as Coffea canephora, which has two main botanical varieties: robusta and nganda. The coffee plant belongs to the genus Coffea in the family Rubiaceae, with some 80 separate species, of which only two are commercially important for green coffee: C. canephora (known in the trade as C. robusta) and C. arabica L.
The genus Coffea comprises 131 species, of which only Coffea arabica L. (Arabica coffee) and C. canephora Pierre ex A. Froehner (Robusta coffee) are cultivated at a commercial scale. C. canephora has the widest native distribution range among all Coffea species, ranging from West Africa through Cameroon, the Central African Republic, the Republic of Congo, the Democratic Republic of Congo (DRC), Uganda, and northern Tanzania, down to northern Angola.
1.2 Global Production and Botanical Character
Coffea canephora represents around 45% of global coffee production, with Coffea arabica constituting most of the remainder. It is easy to care for, has a greater crop yield, has almost double the amount of caffeine and more antioxidants, and is less susceptible to disease than arabica. C. arabica is suitable to growth in the highlands, whereas C. canephora is well adapted to lowland tropical areas.
The plant flowers irregularly, taking about 10–11 months for the berries to ripen, producing oval-shaped beans. Beans from C. canephora tend to have lower acidity, more bitterness, and a more woody and less fruity flavor compared to C. arabica beans.
1.3 Common Forms and Preparations
Robusta coffee is encountered in several forms in both the food industry and the dietary supplement market:
- Roasted whole beans and ground coffee: Most robusta is used for instant coffee. It is also extensively used in espresso blends. It is most commonly used in espresso blends, giving body, bitterness, and an extra dose of caffeine to the final cup.
- Green (unroasted) coffee bean extract (GCBE): Green coffee extract (GCE) is present in green or raw coffee. It is also present in roasted coffee, but much of the GCE is destroyed during the roasting process. In supplement form, GCBE is standardized primarily for its chlorogenic acid content.
- Standardized extracts: Green coffee containing phenolic compounds called chlorogenic acids is available in standardized extract form, such as a robusta extract standardized to 25% chlorogenic acid.
- Instant and soluble coffee powders: These are derived primarily from robusta beans due to their high soluble solids content and cost efficiency.
- Decaffeinated extracts: Decaffeinated green coffee extracts (DGCE) rich in CGAs have been used in clinical trials to isolate the effects of chlorogenic acids from those of caffeine.
During roasting, the chlorogenic acid content decreases while melanoidins are formed as complexes of sugars, amino acids, and chlorogenic acid through the Maillard reaction. Instant coffee or a paper filter on the coffee beans leads to almost complete removal of the diterpenes cafestol and kahweol.
2. Traditional and Historical Use
2.1 Pre-Colonial African Use
Before the European colonization of Africa, Coffea canephora was only grown locally, mainly in the northeastern and southwestern parts of its natural distribution area. Many cultivated coffee varieties descend from Coffea canephora, commonly known as robusta coffee, and the Congo Basin has a century-long history of robusta coffee cultivation and breeding.
The Baganda people of Uganda represent perhaps the most thoroughly documented example of pre-colonial robusta use. Robusta coffee (Coffea canephora) used to grow wild along the northern shores of Lake Victoria, and the Baganda people of the Buganda Kingdom began cultivating it in their household gardens. In their culture, robusta coffee was largely used for traditional and cultural functions like sealing blood brotherhood, initiating new people into the community, or celebrating the birth of twins.
Traditionally, two native robusta varieties have been cultivated in Uganda: Kisansa and Nganga. Kisansa coffee plants can keep producing for several decades, growing up to 10 meters tall, and are resistant to the major plant diseases.
2.2 Early Commercial Cultivation and Colonial Spread
C. canephora was initially cultivated at a small scale in the late 19th century in Gabon, Angola, Uganda, and the Sankuru region of the DRC. At that time, arabica coffee cultivation in Asia was threatened by leaf rust disease, and plant hunters were searching for alternative coffee species from Africa.
The introduction and promotion of Coffea robusta as a robust coffee species by the Belgian horticulturist Linden in 1900 is probably key for the success of robusta coffee, as the commercial name suggests. Linden's introduction was done using seeds of wild plants from the Sankuru province in the Democratic Republic of the Congo. This material was sent to Java, where it was crossed with other robusta lineages from Lower Congo and Uganda. After the arrival of robusta coffee in Java in the early 20th century, Java developed itself into an important breeding and distribution center of robusta coffee.
Native to the tropical forests around Lake Victoria in Uganda, robusta was introduced to Southeast Asia in 1900 after leaf rust (Hemileia vastatrix Berk. and Br.) destroyed all of Ceylon's arabica coffee crops in 1869 and most of the low-lying plantations of Java in 1876.
In the early 1900s, the first robusta coffee research and breeding stations were installed in Central Africa, including the Botanical Garden in Eala. In DR Congo, the INEAC (Institut National pour l'Etude Agronomique du Congo Belge) was created in 1933 to develop a program for scientific research focused on agriculture and forestry, with Yangambi (Tshopo Province, northeastern DR Congo) becoming the principal research station for robusta coffee.
2.3 Modern Geographic Distribution
Vietnam is now the largest producer of robusta coffee, accounting for around 40% of the world's robusta production. This significant proportion places Vietnam second only to Brazil in terms of overall coffee production. Indonesia, Uganda, the Democratic Republic of the Congo, and Brazil also contribute significantly to the global supply of robusta coffee.
Western and Central Africa, Southeast Asia, and Brazil are major producers of robusta coffee. The robusta bean can grow at lower elevations.
3. Key Constituents and Active Compounds
3.1 Overview of Bioactive Profile
Coffee contains more than a thousand compounds, many of which have yet to be fully characterized. Its bioactive components include the most widely known caffeine, along with chlorogenic acids (CGAs), diterpenes, trigonelline, tryptophan alkaloids, and secondary metabolites that are a product of Maillard reactions called melanoidins.
Recent studies have described the presence of phytochemicals with proven bioactive effects in coffee, such as caffeine, polyphenols, trigonelline, caffeic acid, melanoidins, nicotinic acid, flavonoids, CGAs, kahweol, and cafestol. Qualitative phytochemical screening of robusta extracts has identified alkaloids, flavonoids, saponins, and tannins. Quantitative analysis has further revealed secondary metabolites including alkaloids, flavonoids, saponins, tannins, and triterpenoids.
3.2 Caffeine
Caffeine is the dominant and most pharmacologically active alkaloid in robusta coffee. Robusta coffee extracts generally contain twice as much caffeine as arabica, with caffeine content varying from 3.41% per dry mass in some arabica types to 8.16% in robusta coffee from Indonesia. Chlorogenic acids and caffeine are important for flavor formation as well as the health effects of green coffee brews and their extracts.
In terms of absolute content per bean, robusta presents the highest content of caffeine. The robusta variety is richer in secondary metabolites than arabica coffee; in particular, its caffeine content is usually reported as twice the concentration found in arabica coffee.
3.3 Chlorogenic Acids (CGAs)
With significant variation, the total coffee CGAs amount to approximately 7.0–14.4% of dry matter present in green robusta and 4.0–8.4% in green arabica beans. Chlorogenic acids are hydroxycinnamoyl esters of quinic acids, plant secondary metabolites that are ubiquitous in the plant kingdom and are among the most abundant dietary phenolics in an average diet.
Significant variations between robusta and arabica have been observed for feruloyl quinic acids, dicaffeoyl quinic acids, and 5-sinapoylquinic acid, while the mono-caffeoyl quinic acids showed no variation when the two coffee varieties were compared. The predominant individual CGA isomer in both species is 5-O-caffeoylquinic acid (5-CQA). In both arabica and robusta, 5-CQA is the major component, and progressive roasting decreases the concentration of all CGAs.
Roasting has a significant degrading effect on CGA content. Roasting destroys chlorogenic acid steadily; dark roasting has been found to reduce three major chlorogenic acid compounds by 39% to 44%, while caffeine levels stayed essentially unchanged regardless of roast level. A dark roast therefore provides the same caffeine content but strips away a significant portion of the antioxidants that make robusta nutritionally interesting.
Robusta coffee also contains caffeic acid (bound to quinic acid as CGA), p-coumaroylquinic acids, and feruloylquinic acids.
3.4 Trigonelline, Diterpenes, and Other Constituents
Compared with robusta green beans, arabica green beans have substantially higher lipid, sucrose, and trigonelline contents, but lower caffeine and chlorogenic acid (CGA) contents. Robusta therefore contains lower levels of the diterpenes cafestol and kahweol relative to arabica. Diterpenes like cafestol and kahweol exhibit important antioxidant and chemoprotective properties but have also been associated with raised serum cholesterol levels.
Lipids, caffeine, chlorogenic acids, quinic acid, trigonelline, proteins, amino acids, and carbohydrates are among the chemical markers that have been used to discriminate between genetic groups of C. canephora.
Roasting of coffee beans induces a marked increase in melanoidins, which are the major contributor to brewed coffee's color, flavor, and health-promoting properties. The main contributors to coffee's anti-inflammatory activity include diterpenes, caffeine, trigonelline, and CGAs.
4. Established Mechanisms of Action
4.1 Caffeine: Adenosine Receptor Antagonism
Caffeine's primary mechanism of action involves its effects on adenosine receptors in the brain. Being both fat- and water-soluble, caffeine easily crosses the blood-brain barrier and antagonizes all 4 adenosine receptor subtypes (A1, A2a, A2b, and A3). The antagonism of the A2a receptor is particularly responsible for caffeine's wakefulness effects.
The behavioral effects of caffeine appear likely to be due in large measure to antagonism of the action of endogenous adenosine at A1- and A2a-receptors in the central nervous system. Other biochemical mechanisms of action of caffeine, such as release of intracellular calcium, inhibition of phosphodiesterases, and blockade of regulatory sites of GABAA receptors, would require much higher concentrations than the micromolar concentrations of caffeine associated with behavioral stimulation.
Due to the blocking of adenosine inhibitory effects through its receptors, caffeine indirectly affects the release of norepinephrine, dopamine, acetylcholine, serotonin, glutamate, and gamma-aminobutyric acid.
Adenosine receptors are not limited to the CNS but are present throughout the body. Direct antagonism of receptor A1 in cardiac muscles results in positive inotropic effects. Likewise, adenosine receptor antagonism stimulates the release of catecholamines, contributing to the systemic stimulatory effects of caffeine and further stimulating cardiac inotropy.
4.2 Caffeine: Phosphodiesterase Inhibition and Vascular Effects
A secondary effect of caffeine is the inhibition of phosphodiesterases, with the subsequent accumulation of cyclic adenosine monophosphate (cAMP) and an intensification of the effects of catecholamines. In vascular smooth muscle cells, caffeine's effect is predominantly a competitive inhibition of phosphodiesterase, producing an accumulation of cAMP and vasodilation; it also blocks the adenosine receptors present in vascular tissue to produce vasoconstriction.
4.3 Chlorogenic Acids: Antioxidant, Anti-Inflammatory, and Metabolic Effects
Green coffee bean extract (GCBE) has been hypothesized to be an antihypertensive agent due to its antioxidant, anti-inflammatory, anti-stress properties, and beneficial effects on endothelial cells and adipokines.
Chlorogenic acids have been found to have an antagonistic effect on glucose absorption in the intestine, and may also induce weight loss by inhibiting glucose creation from the metabolism of carbohydrates, thus inducing higher rates of metabolism in the body. Chlorogenic acids inhibit glucose-6-phosphatase, thereby curtailing the formation of glucose from gluconeogenesis and glycogenolysis.
Coffee bioactives including CGAs have anti-inflammatory, antioxidant, antifibrotic, antimicrobial, and anti-cancer properties that have been linked to a beneficial role in lowering all-cause mortality and improving endocrine, liver, gastrointestinal, cardiovascular diseases, cancers, and neurocognitive function.
5. Scientific Evidence by Area of Use
5.1 Cardiovascular Health: Blood Pressure
The cardiovascular effects of robusta-derived green coffee extract and its chlorogenic acids have been among the most studied areas in human clinical research.
A meta-analysis published in Phytotherapy Research (2019) systematically reviewed the evidence from randomized controlled trials (RCTs): the evidence from published RCTs suggests that CGA intake causes statistically significant reductions in systolic and diastolic blood pressures, with the size of the effect being moderate.
A more recent and comprehensive 2022 systematic review and dose-response meta-analysis searched PubMed/Medline, Scopus, Web of Science, and Embase for clinical trials on GCBE and blood pressure. The analysis concluded that GCBE has the potential as a hypertension-reducing supplement in hypertensive patients; however, GCBE did not significantly change heart rate.
A 2021 meta-analysis specifically examining cardiovascular risk factors included 15 studies (19 arms) comprising 637 participants. The results indicated that green coffee bean extract significantly reduced systolic blood pressure by −3.08 mmHg (95% CI: −4.41, −1.75), diastolic blood pressure by −2.27 mmHg (95% CI: −3.82, −0.72), total cholesterol by −5.93 mg/dl (95% CI: −9.21, −2.65), fasting plasma glucose by −2.21 mg/dl (95% CI: −3.94, −0.48), body weight by −1.24 kg (95% CI: −1.82, −0.66), and BMI by −0.55 kg/m² (95% CI: −0.88, −0.22). No significant effect was detected for triglycerides, HDL-C, HbA1C, and HOMA-IR.
At the level of mechanism, a randomized crossover trial in healthy subjects tested three doses of decaffeinated green coffee extract (DGCE). Investigators conducted a double-blind randomized crossover trial to test the effect of acute consumption of a decaffeinated green coffee extract rich in CGAs on endothelial function in healthy subjects, comparing 302 mg, 604 mg, and 906 mg DGCE with a placebo, using flow-mediated dilation (%FMD) as the measure of endothelial function. The trial demonstrated an acute improvement in %FMD over time after ingestion of DGCE, explained at least partly by the presence in the blood circulation of CGAs and their metabolites.
A specific earlier trial cited in the literature found that consumption of drinks containing 140 mg of chlorogenic acid for 12 weeks significantly reduced systolic blood pressure (SBP) and diastolic blood pressure (DBP) compared to the placebo group.
Evidence strength: The blood pressure evidence is the strongest area for GCBE/CGA clinical research. Multiple RCTs and at least three meta-analyses show consistent modest reductions in blood pressure. Effect sizes are statistically significant but modest in absolute magnitude. Limitations include heterogeneity across studies in terms of CGA doses used, duration of supplementation, and study populations.
5.2 Body Weight and Metabolic Health
A systematic review and meta-analysis (Onakpoya et al., 2011, PMC) evaluated the efficacy of green coffee extract as a weight loss supplement. Five eligible trials were identified, and three were included. All studies were associated with a high risk of bias. The meta-analytic result reveals a significant difference in body weight with GCE compared with placebo (mean difference: −2.47 kg; 95% CI: −4.23, −0.72). The magnitude of the effect is moderate and there is significant heterogeneity among studies. It was concluded that the results from these trials are promising but the studies are all of poor methodological quality, and more rigorous trials are needed to assess the usefulness of GCE as a weight loss tool.
Clinical trials on weight loss characteristics of GCE and CGA are controversial and contradictory, and a subsequent comprehensive systematic review and dose-response meta-analysis was undertaken to examine the effect of GCE and CGA intervention on body weight, BMI, and waist circumference in adults.
In terms of specific components, a small RCT (n=26) in patients with non-alcoholic fatty liver disease (NAFLD) and diabetes examined caffeine and chlorogenic acid supplementation over 12 weeks. The aim was to determine the effects of caffeine and chlorogenic acid supplementation on gut microbiota and metabolic disturbances. Patients were randomly assigned to receive either 200 mg caffeine plus 200 mg chlorogenic acid, or 200 mg caffeine plus placebo, or 200 mg chlorogenic acid plus placebo, or double placebo. After 3 months, patients in the intervention groups showed a significant decrease in body weight (combined caffeine+CGA group: −3.69 kg vs. placebo: +0.26 kg), with the combined group losing significantly more than all other groups.
Evidence strength: Preliminary to moderate. Early meta-analyses were based on low-quality trials. More recent meta-analyses show statistically significant but modest effects on body weight and BMI. High heterogeneity and risk of bias limit confidence. The combined supplementation evidence remains very limited in sample size.
5.3 Glycemic Control
Anti-diabetic activities have been reported for caffeine, chlorogenic acid, and ferulic acid (key robusta constituents) in the scientific literature. The 2021 meta-analysis of 15 RCTs found a significant reduction in fasting plasma glucose of −2.21 mg/dl (95% CI: −3.94, −0.48) with GCBE supplementation, though no significant effect was detected for HbA1C and HOMA-IR.
The mechanistic basis involves inhibition of intestinal glucose transport and glucose-6-phosphatase activity, as outlined in Section 4.3. Evidence strength: Modest, based primarily on meta-analyses of heterogeneous trials; effects on established markers of long-term glycemic control (HbA1C) were not significant.
5.4 Neuroprotection and Cognitive Function
Robusta coffee (Coffea canephora) and its bioactive compounds demonstrate significant antioxidant, anti-inflammatory, and neuroprotective properties. Evidence from preclinical and epidemiological studies suggests that these compounds can modulate multiple pathways involved in neurodegenerative processes, including oxidative stress, neuroinflammation, and protein aggregation, in conditions such as Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.
Coffee intake can decrease the risk for Parkinson's disease. Its beneficial effects are allegedly mediated by caffeine through adenosine A2A receptor antagonist action. A small human study in Parkinson's disease patients used PET scanning to directly measure striatal A2A receptor occupancy by caffeine after ingestion of coffee. Five patients with PD underwent ¹¹C-preladenant PET scanning at baseline and after intake of coffee containing 129.5 mg (n=3) or 259 mg (n=2) of caffeine. The mean serum caffeine level increased from 0.374 μg/mL at baseline to 4.48 and 8.92 μg/mL, respectively.
At a preclinical level, outcomes from animal studies indicated that memory deficits appearing with age are reversed by oral administration of caffeine, and that the applied treatment contributes to normalization of enhanced levels of reactive oxygen and nitrogen species and inhibited Na⁺/K⁺-ATPase activity in the brain of elderly rats.
Evidence strength: The neuroprotective evidence for caffeine is among the most consistently supported by epidemiological data; however, direct human clinical trials using robusta coffee specifically for neurological outcomes are lacking. Most mechanistic evidence is preclinical (animal) or inferred from epidemiological studies of general coffee consumption. Robusta-specific clinical neuroprotection trials have not yet been conducted.
5.5 Antioxidant Activity
A number of pharmacological activities are attributed to robusta's bioactive components, including antioxidant, anti-inflammatory, immunomodulatory, antimicrobial, anti-cancer, cardioprotective, and neuroprotective effects.
Regular consumption of coffee has been found to reduce susceptibility to LDL oxidation, a pathway involved in atherosclerotic plaque development, thus favoring endothelial function. Some coffee components, especially phenolics including chlorogenic acid and ferulic acid, have a great antioxidant capacity.
A crossover RCT in 15 healthy male volunteers examined CGA-enriched coffee. The effects of repeated intake of coffee containing CGA with or without hydroxyhydroquinone (HHQ) on postprandial fat oxidation and oxidative stress in healthy male volunteers were assessed. Animal studies have revealed that HHQ likely inhibits the antihypertensive effects of CGA by promoting oxidative stress, and human clinical trials also demonstrated that CGA in HHQ-reduced coffee has antihypertensive effects.
Evidence strength: Antioxidant activity of robusta's CGAs is well established at both in vitro and in vivo biochemical levels. Human clinical evidence for specific clinical outcomes attributable to antioxidant activity alone remains indirect and of moderate strength.
5.6 Anticancer / Chemopreventive Activity
A 2021 laboratory study published in Oxidative Medicine and Cellular Longevity (PMC8154281) directly investigated freeze-dried robusta coffee extracts on cancer cell lines. Coffee intake has been hypothesized to reduce the risk of breast cancer, but the current evidence is inconclusive. Green and dark coffee extract significantly reduced viability in human breast, colorectal, brain, and bone cancer cells. Coffee anticancer activity was clearly evidenced in MDA-MB-231 (ER-) and MCF-7 (ER+) breast cancer cells but not in the normal breast cell line. In addition, coffee extract induced an increase in S-phase and a decrease in G2/M population in breast cancer cells, affected mitochondrial morphology, and triggered apoptosis. MDA-MB-231 breast cancer cells lost their clonogenic capacity after treatment.
Various health benefits of coffee have recently been studied, with special emphasis on its protective effect against DNA damage. Previous research demonstrated that coffee has important antioxidant capacities in prostate cancer cells, decreasing cell proliferation and inducing programmed cell death through apoptosis.
The mechanisms responsible for the chemopreventive coffee effects continue to be studied for a better understanding.
Evidence strength: Preliminary. The anticancer evidence for robusta coffee specifically is limited to cell-line (in vitro) studies. No human clinical trials have been conducted with robusta coffee as a cancer intervention. Epidemiological associations between general coffee consumption and reduced risk of certain cancers exist in the broader literature but are not robusta-specific.
5.7 Hepatoprotective Effects
Hepatoprotective activity has been reported for chlorogenic acid in the scientific literature. The consumption of coffee is associated with a small reduction in mortality in women with hepatic disease and/or cirrhosis and shows a protective effect on the liver in hepatic cancer.
Evidence strength: The hepatoprotective associations are primarily derived from epidemiological studies of general coffee consumption rather than robusta-specific intervention trials. The mechanistic evidence involves chlorogenic acid, which is a major constituent of robusta, but species-specific human clinical data are lacking.
5.8 Oral Health (Salivary pH)
A published literature review analyzed 15 studies on the effect of robusta coffee on salivary pH. The review reveals that robusta coffee (Coffea canephora) causes a decrease in the acidity (pH) of saliva. This occurs because higher concentrations of coffee produce more acidic pH, but several studies report that low concentrations of robusta coffee do not cause a decrease in salivary pH.
Evidence strength: Moderate in terms of the direction of the effect (dose-dependent decrease in salivary pH at higher concentrations). The clinical implications for dental health require further study.
6. Body Systems and Health Areas Associated with Robusta Coffee
- Central nervous system: Stimulant and alertness-enhancing effects via adenosine receptor antagonism; neuroprotective associations (Parkinson's disease, Alzheimer's disease) primarily from epidemiological data and preclinical studies.
- Cardiovascular system: Moderate reductions in blood pressure supported by multiple RCTs and meta-analyses; acute improvement in endothelial function (FMD) demonstrated in human trial.
- Metabolic/endocrine system: Modest reductions in fasting glucose, body weight, and BMI in RCTs; inhibition of intestinal glucose uptake and glucose-6-phosphatase as proposed mechanisms.
- Gastrointestinal system: Coffee bioactives have been linked to improving gastrointestinal diseases. Potential prebiotic effects of CGAs have been noted though the evidence base is limited.
- Hepatic system: Epidemiological associations between coffee consumption and reduced risk of liver disease and liver cancer, mediated in part by CGA and caffeine.
- Oral cavity: Dose-dependent decrease in salivary pH documented across multiple studies.
- Oncology (preclinical): In vitro reductions in cancer cell viability and induction of apoptosis in breast, colorectal, brain, and bone cancer cell lines.
- Renal system: The effects of caffeine on the kidney — diuresis, increased blood flow, and renin secretion — appear to be due to an action of caffeine at adenosine receptors.
7. Dosage Forms and Dosages Reported in Studies
The following dosages are cited directly from the research literature; they describe what was used in specific studies and are not recommendations.
- Green coffee bean extract (GCBE), blood pressure studies: 140 mg of chlorogenic acid per day for 12 weeks was used in one clinical trial that significantly reduced systolic and diastolic blood pressure.
- Decaffeinated green coffee extract (DGCE), endothelial function: A double-blind randomized crossover trial compared 3 different doses of DGCE (302 mg, 604 mg, and 906 mg) with placebo in healthy subjects.
- Caffeine plus chlorogenic acid combination: A randomized controlled trial used 200 mg caffeine plus 200 mg chlorogenic acid, or 200 mg caffeine alone, or 200 mg chlorogenic acid alone, for 12 weeks in patients with NAFLD and diabetes.
- Meta-analysis pooled effect on body weight: The meta-analytic result across green coffee extract trials reveals a mean difference in body weight of −2.47 kg (95% CI: −4.23, −0.72) compared with placebo.
- Meta-analysis pooled blood pressure effects: Across 15 RCTs (637 participants), GCBE was associated with reductions in systolic blood pressure of −3.08 mmHg (95% CI: −4.41, −1.75) and diastolic blood pressure of −2.27 mmHg (95% CI: −3.82, −0.72).
- Standardized extract concentration: Green coffee robusta extract standardized to 25% chlorogenic acid has been described as a supplement form in patent literature.
8. Safety Considerations and Interactions
8.1 Caffeine Toxicity Threshold and Adverse Effects at High Doses
Doses of 1,000 mg of caffeine (approximately 15 mg/kg body weight) have generated detrimental side effects, with early symptoms being insomnia, restlessness, and agitation. These symptoms may progress to mild delirium, emesis, and convulsions. Other symptoms can include tachycardia, asystole, and rapid respiration.
With respect to actions of caffeine on the central nervous system, it has been shown that ingestion of very high doses of caffeine can produce undesirable effects on mental function such as fatigue, nervousness, and feelings of anger or depression.
Because robusta coffee contains roughly double the caffeine of arabica, the per-serving caffeine exposure is substantially higher. A standard 8-ounce cup of drip-brewed robusta delivers around 265 mg of caffeine, compared to roughly 170 to 200 mg for a typical arabica brew.
8.2 Cardiovascular Interactions
Adenosine receptors are present throughout the body, not just the CNS. Direct antagonism of receptor A1 in cardiac muscles results in positive inotropic effects. Adenosine receptor antagonism also stimulates the release of catecholamines, contributing to systemic stimulatory and cardiac effects. There is considerable variability in the cardiovascular and neuropsychologic response to coffee drinking, which may have a genetic basis.
8.3 Hepatic Metabolism and Liver Disease
Individuals with advanced cirrhosis may experience delayed caffeine metabolism, leading to adverse drug reactions such as insomnia, nervousness, and headaches, even at intake levels that are typically well tolerated by individuals without liver disease. While caffeine may offer modest protective effects against the progression of chronic liver disease, energy drinks containing harmful supplements may contribute to liver injury.
8.4 Pregnancy and Lactation
Epidemiological studies have revealed that caffeine consumption during pregnancy is associated with adverse gestational outcomes, yet the underlying mechanisms remain obscure. Animal studies with physiologically relevant dosages have begun to dissect adverse effects of caffeine during pregnancy with respect to oviduct contractility, embryo development, uterine receptivity, and placentation.
Research has found associations between caffeine intake and pregnancy loss, low birth weight, cardiac and genital anomalies, higher body mass, and neurodevelopmental and neurobehavioral outcomes. The effects were often dose dependent. Defining a safe dose for caffeine intake during pregnancy is a challenging task due to heterogeneity in study designs and results. In some studies, exposures below the commonly recommended 200 mg/day guideline were associated with pregnancy loss, low birth weight, cardiac and genital anomalies, and neurodevelopmental outcomes.
Caffeine readily crosses the placental barrier; caffeine's elimination half-life increases in late gestation; and infants poorly metabolize caffeine until 3 months of age. Given that robusta delivers significantly higher caffeine per cup than arabica, this is a particularly relevant consideration for robusta beverages and extracts.
8.5 Early Brain Development
Caffeine has also been noted for adverse effects on brain development at early stages and on reproductive systems.
8.6 Gastrointestinal Tolerance
Robusta contains higher levels of caffeine and chlorogenic acids, along with a more pronounced presence of quinic acid, all of which can contribute to increased bitterness and potential digestive discomfort. During roasting, chlorogenic acids break down into quinic acid and caffeic acid. Quinic acid specifically correlates with harsh, astringent bitterness.
8.7 Drug Interactions and CYP Metabolism
The high genetic variability of CYP1A2 activity and the lack of objective measurements of plasma caffeine clearance present challenges in predicting individual caffeine metabolism. Caffeine is primarily metabolized by the cytochrome P450 enzyme CYP1A2. Drugs or substances that inhibit CYP1A2 (such as fluvoxamine, quinolone antibiotics, and estrogen-containing oral contraceptives) can substantially increase caffeine blood levels, while inducers (such as smoking) can decrease them. Given robusta's high caffeine load, these interactions carry amplified potential significance compared with arabica-based preparations.
8.8 Cholesterol and Diterpenes
Instant coffee or a paper filter on the coffee beans leads to almost complete removal of the diterpenes cafestol and kahweol. Diterpenes like cafestol and kahweol exhibit important antioxidant and chemoprotective properties but have also been associated with raised serum cholesterol levels. Robusta contains lower levels of these diterpenes than arabica, so the cholesterol-raising effect via diterpenes is expected to be lower in robusta preparations; however, unfiltered robusta preparations retain some diterpene content.
8.9 Safety Data from Clinical Trials
Across the RCTs included in at least one systematic review examining CGA supplementation effects on blood pressure, all studies reported no adverse events. More advanced pre-clinical and clinical trials are recommended to investigate the safety profiles of these coffee components before their use as possible therapeutics.
References
Go back